Kymora Scotland, MD
Urology · Los Angeles, CANPI 1093005787
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (34.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by KARL Storz Endoscopy-america at 26.3% of the total. Reporting peaked in 2022 at $4,034 and has fallen 81.5% since, to $746 in 2025.
Across 84 payments — averaging $140.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- KARL Storz Endoscopy-america$3K
- Boston Scientific$3K
- Cook Incorporated$2K
- Cook Medical LLC$1K
- Ambu A/s$800
- Ambu Inc.$311
- plus $2K from 13 others
What the payments were for
- Consulting fees$4,01934%
- Speaking & faculty fees$2,32520%
- Grants$1121%
- Travel & lodging$1,52413%
- Food & beverage$3,83032%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| KARL Storz Endoscopy-america | 7 | $3,108 |
| Boston Scientific | 22 | $2,662 |
| Cook Incorporated | 1 | $2,325 |
| Cook Medical LLC | 11 | $1,079 |
| Ambu A/s | 1 | $800 |
| Ambu Inc. | 2 | $311 |
| Medtronic | 2 | $273 |
| Progenics Pharmaceuticals, Inc. | 2 | $228 |
| C. R. Bard, Inc. & Subsidiaries | 12 | $222 |
| Procept Biorobotics Corporation | 1 | $205 |
| Rochester Medical Corporation | 15 | $171 |
| Urogen Pharma, Inc. | 1 | $165 |
| Covidien LP | 1 | $94 |
| Bayer | 1 | $75 |
| AbbVie | 1 | $35 |
| BD | 1 | $24 |
| Calyxo, Inc. | 1 | $19 |
| Laborie Medical Technologies Corp. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SCOPESAFELASER FIBER$2,494
- NCircle$2,325
- Flex-X$525
- Cook Medical Urology$497
- LithoVue$288
- PYLARIFY$228
- AquaBeam Robotic System$205
- FIBER DUST$202
- INTERSTIM$178
- JELMYTO$165
- GENERAL KIDNEY STONE DISEASE$149
- GENERAL - THERAPIES$141
- Cook$136
- GENERAL BPH$112
How this compares
$11,810 in reported general payments places this provider in the 80th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 34 | $947 |
| Tamsulosin Hcl | 48 | $434 |
Paid to pharmacies, not to this prescriber.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.